[Medical therapy in revascularized coronary artery disease patients].
OBJECTIVE
To evaluate the status of medical therapy in the revascularized coronary artery disease (CAD) patients treated in Anzhen Hospital.


METHODS
2048 CAD patients who received revascularization during July 2003 to June 2004 were registered in DESIRE database. The methods of revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)] and use of medicines [aspirin, betablocker (BB), statins, angiotension converting enzyme inhibitor (ACEI) etc] during hospitalization and during the follow-up were recorded. The patients were followed up for a mean time of 587 +/- 127 days.


RESULTS
The prescription rates of aspirin, BB, statins, and ACEI were 93.9%, 88.9%, 67.7%, and 62.9% respectively. 58.9% of the patients used combined aspirin, BB, and statins; and 39.7% of the patients used combined aspirin, BB, statins, and ACEI. The prescription rates of these drugs was all significantly higher in the PCI group than in the CABG group (all P < 0.001). The prescription rates of these drugs during follow-up were 90.8%, 57.4%, 43.0%, and 24.5% respectively, all significantly lower than those during hospitalization (all P < 0.001). The prescription rates of these medicines were all significantly higher in Beijing compared with in the areas other than Beijing (all P < 0.001).


CONCLUSIONS
The CAD patients who received revascularization show a high proportion of using secondary prevention drugs during hospitalization, and the prescription rates of these drugs decrease significantly during follow-up, especially in those who received CABG and who live outside Beijing.
Liu
Xiao-Hui
XH
Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Science, Beijing 100029, China.
DU
Xin
X
Kang
Jun-Ping
JP
Lü
Qiang
Q
Zhang
Qiang
Q
Lü
Shu-Zheng
SZ
Chen
Fang
F
Ma
Chang-Sheng
CS
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002681:China; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000628:therapy; D019992:Databases as Topic / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D005500:Follow-Up Studies; D006761:Hospitals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin